Foluso Agboola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Foluso Agboola has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Steven D Pearson
Institute for Clinical and Economic Review (ICER), Boston, MA
4 shared publicationsDavid M Rind
Institute for Clinical and Economic Review (ICER), Boston, MA
3 shared publicationsSerina Herron-Smith
Institute for Clinical and Economic Review (ICER), Boston, MA. USA
3 shared publicationsAbigail C. Wright
Institute for Clinical and Economic Review (ICER), Boston, MA, 02108, USA
2 shared publicationsDavid Rind
Institute for Clinical and Economic Review, Boston, MA
2 shared publicationsEmily Nhan
Institute for Clinical and Economic Review (ICER), Boston, MA
2 shared publications
Latest Publications
- Open Access
- 3 March 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (3)
ICER's launch price and access report: 5 key takeaways and 5 questions we should all be asking
Improving prescription drug affordability and patient access remains a key policy objective in the US health care system, yet not every proposed solution will help us achieve this goal. To contribute to this ongoing policy discussion, the Institute for Clinical and Economic Review (ICER) published a report in October 2025 to evaluate the launch prices of new Food and Drug Administration (FDA)-approved drugs and patient access to those therapies. This article highlights five key takeaways from the report and proposes five critical questions for consideration. Based on findings from ICER's Launch Price and Access report, this article offers key recommendations to move the US health care system toward one that pays for value and delivers affordable access for patients, while driving the next wave of innovation.
- 3 March 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (3)
Open AccessICER's launch price and access report: 5 key takeaways and 5 questions we should all be asking
Improving prescription drug affordability and patient access remains a key policy objective in the US health care system, yet not every proposed solution will help us achieve this goal. To contribute to this ongoing policy discussion, the Institute for Clinical and Economic Review (ICER) published a report in October 2025 to evaluate the launch prices of new Food and Drug Administration (FDA)-approved drugs and patient access to those therapies. This article highlights five key takeaways from the report and proposes five critical questions for consideration. Based on findings from ICER's Launch Price and Access report, this article offers key recommendations to move the US health care system toward one that pays for value and delivers affordable access for patients, while driving the next wave of innovation.
- 22 February 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 169, 111299
A framework for evaluating the diversity of clinical trials
- 22 February 2024
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 169, 111299
A framework for evaluating the diversity of clinical trials
- 25 May 2023
- Published by Elsevier in Value in Health
- Vol. 26 (9) , 1345-1352
Evaluation of Diversity of Clinical Trials Informing Health Technology Assessments in the United States: A 5-Year Analysis of Institute for Clinical and Economic Review Assessments
- 25 May 2023
- Published by Elsevier in Value in Health
- Vol. 26 (9) , 1345-1352
Evaluation of Diversity of Clinical Trials Informing Health Technology Assessments in the United States: A 5-Year Analysis of Institute for Clinical and Economic Review Assessments
- Open Access
- 1 May 2023
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 29 (5) , 569-575
Medications for obesity management: Effectiveness and value
- 1 May 2023
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 29 (5) , 569-575
Open AccessMedications for obesity management: Effectiveness and value
- Open Access
- 1 January 2022
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 28 (1) , 108-114
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and E...
- 1 January 2022
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 28 (1) , 108-114
Open AccessJAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and E...
- Open Access
- 1 July 2021
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 27 (7) , 961-966
The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan ...
- 1 July 2021
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 27 (7) , 961-966
Open AccessThe effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan ...
- Open Access
- 1 May 2021
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 27 (5) , 667-673
The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER’s annual policy summit is supported by dues from AbbVie, Aetna, America’s Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, uniQure, and United Healthcare. Agboola, Rind, Herron-Smith, and Pearson are employed by ICER. Walton and Quach, through the University of Illinois at Chicago, received funding from ICER for development of the economic model described in this report.
- 1 May 2021
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 27 (5) , 667-673
Open AccessThe effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER’s annual policy summit is supported by dues from AbbVie, Aetna, America’s Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, uniQure, and United Healthcare. Agboola, Rind, Herron-Smith, and Pearson are employed by ICER. Walton and Quach, through the University of Illinois at Chicago, received funding from ICER for development of the economic model described in this report.
- 1 May 2020
- Published by Elsevier in Value in Health
- Vol. 23, S261
PND15 LONG-TERM COST-EFFECTIVENESS OF LASMIDITAN, UBROGEPANT AND RIMEGEPANT FOR TREATMENT OF ACUTE MIGRAINE
- 1 May 2020
- Published by Elsevier in Value in Health
- Vol. 23, S261
PND15 LONG-TERM COST-EFFECTIVENESS OF LASMIDITAN, UBROGEPANT AND RIMEGEPANT FOR TREATMENT OF ACUTE MIGRAINE